Clinical trial
Meta-Analysis of the Safety and Efficacy of Natalizumab in Pediatric Patients With Multiple Sclerosis
NCT02137109 is registered in ClinicalTrials.gov with Biogen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Meta-Analysis of the Safety and Efficacy of Natalizumab in Pediatric Patients With Multiple Sclerosis
- Lead sponsor
- Biogen
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 31, 2014
- Completion date
- October 31, 2015
- Enrollment
- 400 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.